graftjacket® Xpress
flowable soft tissue scaffold

Flowable, acellular soft tissue treatment for tunneling and irregularly contoured wounds.

structured wound-healing therapies from KCI
Tunneling and irregularly contoured wounds pose significant challenges.

- **Risk.** In the lower extremity, sinus tract wounds are a significant risk for osteomyelitis.¹

- **Loss of quality of life.** Patients may lose their ability to work and enjoy the things that matter most to them.

- **Damage.** Tunneling and irregularly contoured wounds may destroy soft tissues and bones; quick action and quality wound care treatment are critical.

- **Lack of effective options.** Available products to support treatment have traditionally been manufactured in sheet form and may not be suited for filling deep tunneling wounds.
KCI presents Graftjacket® Xpress flowable soft tissue scaffold.

An innovative treatment for tunneling and irregularly contoured wounds.

Graftjacket® Xpress flowable soft tissue scaffold (FSTS) is a micronized form of Graftjacket® regenerative tissue matrix (processed acellular human dermis) that retains the natural biological components of human dermis necessary to aid the body in wound healing by supporting regeneration of host tissue. When reconstituted with sterile saline and applied to the wound following best practices for wound care, Graftjacket® Xpress FSTS:

- Conforms to the shape of the wound and fills deep tunneling and irregularly contoured wounds.
- May minimize the need for more extensive surgical intervention for some ‘hard to heal’ patients.¹
- Replaces damaged or missing dermal tissue with ‘like’ tissue by supporting cellular repopulation and revascularization by host tissue.
- Helps allow the patient to heal the wound, which may reduce the likelihood of amputation.

Applying Graftjacket® Xpress FSTS

Reconstitute with sterile saline. Attach the flexible applicator tip and apply Graftjacket® Xpress FSTS directly into the debrided, clean wound. Graftjacket® Xpress FSTS fills the irregular contours of the tunneling wound.
Case Study: Scheduled below knee amputation avoided.

For tunneling wounds, Graftjacket® Xpress FSTS should be utilized in conjunction with best practices in wound care, including adequate debridement and infection management when appropriate.

**Situation**

- 74 year-old, insulin dependent diabetic female had two ulcers on the plantar and lateral aspects of her left foot.
- Physician recommended below the knee amputation.
- Patient requested other treatment options be explored.

**Treatment**

- With the patient’s consent, Graftjacket® regenerative tissue matrix was selected to treat both ulcers.
- Plantar ulcer was debrided and grafted with Graftjacket® regenerative tissue matrix.
- Lateral ulcer was debrided, but found to have tunneled down to bone; additional clinical intervention was required.
- Flowable Graftjacket® Xpress FSTS was applied to completely fill the wound.

**Outcome**

- 6 days post treatment, the original wound size had reduced by 50%.
- Within 2 weeks, the wound was considered superficial.
- After 8 weeks, the wound had completely healed. Amputation was no longer deemed necessary.

Case images courtesy of Steven Brigido, DPM and David Armstrong, DPM; used by permission.

As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient’s circumstances and condition.
Figure 1. Preoperative

Figure 2. Debrided ulcer tunneled to bone

Figure 3. Graftjacket® Xpress FSTS was used to fill the wound completely

Figure 4. Five days postoperative

Figure 5. 13 days postoperative; wound is at skin level

Figure 6. Eight weeks postoperative
Positive healing outcomes.

Graftjacket® Xpress FSTS has been shown to help heal chronic, tunneled wounds.

A retrospective series of 12 patients with deep tunneling wounds
Author: Dr. Stephen Brigido, DPM

Objective
To evaluate the healing rates at 12 weeks of patients with deep tunneling wounds (N = 12) treated with Graftjacket® Xpress FSTS.

Results and conclusions

- 50% wound reduction for all patients after 2 weeks.
- 83% of patients achieved complete wound healing within 12 weeks.

Time to healing – wound depth and closure

The author concluded:
The results from this study suggest a unique ability of the “injectable human matrix” [Graftjacket® Xpress FSTS] to help facilitate the body’s ability to rapidly fill deep tunneling wounds and support new tissue formation within the depth of the tunneling wound.¹
For deep tunneling and irregularly contoured wounds, Graftjacket® Xpress FSTS offers a conformable alternative that effectively fills these particularly challenging wounds.

- Flowable form allows product to conform to the irregular contours of deep tunneling wounds.
- Single application may minimize repeated patient visits.
- Replaces damaged or missing dermal tissue with ‘like’ tissue by supporting cellular repopulation and revascularization by host tissue.
- Easy application to tunneling wounds via syringe with flexible applicator tip.

**ordering information**

<table>
<thead>
<tr>
<th>Product code</th>
<th>HRI Number</th>
<th>Product size</th>
</tr>
</thead>
<tbody>
<tr>
<td>GJX</td>
<td>9979300202</td>
<td>2cc</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product code</th>
<th>HRI Number</th>
<th>Product size</th>
<th>Thickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>GJ44</td>
<td>9978251644</td>
<td>4 x 4cm</td>
<td>Thin (0.38 - 1.02mm)</td>
</tr>
<tr>
<td>GJ48</td>
<td>9978253248</td>
<td>4 x 8cm</td>
<td>Thin (0.38 - 1.02mm)</td>
</tr>
</tbody>
</table>

**reference**


Every patient is different and patient results may vary. Before use, physicians must review all risk information and essential prescribing information which can be found in the Graftjacket® Xpress flowable soft tissue scaffold *Instructions for Use*. 

**Ordering information**

1.800.275.4524

**Reimbursement**

KCIreimbursement@trgltd.com
1.866.567.5498

graftjacketbykci.com
www.kci1.com

© 2011 KCI Licensing, Inc. All rights reserved. Graftjacket is a trademark of Wright Medical Technology, Inc. All other trademarks designated herein are proprietary to KCI Licensing, Inc., its affiliates and/or licensors. For US use only. Products processed by LifeCell Corporation for KCI. DSL#11-0476 (Rev 1/12)